TENX Tenax Therapeutics Inc.: ערך חשבונאי למניה

An analysis of the book value per share demonstrates the financial stability of Tenax Therapeutics (TENX), where 3.54 expresses the latest level of the metric. This trend is supported by compliance with environmental standards regarding the disposal of laboratory waste. The business foundation is based on strategic alliances with research centers to develop cardiovascular drugs. Profit potential is driven by the creation of medications for pulmonary hypertension and right-heart pathologies.

For Tenax Therapeutics (TENX), which relies entirely on external contractors (CRO/CMO) due to a lack of in-house facilities, analyzing the book value per share is critical for assessing the actual volume of assets per share. This indicator is calculated as the ratio of net equity to the number of shares, allowing investors to determine the fundamental asset balance and avoid overpaying for the company during periods of market uncertainty.